SERB S.a.r.l.

Based in Luxembourg, SERB S. a. r. l.

specializes in essential medicines for complex and life-threatening conditions, particularly focusing on rare diseases and emergency care for healthcare providers across the globe. SERB S. a. r.

l. is a pharmaceutical company that focuses on essential medications for critical medical needs. Founded in 2013, it is headquartered in Luxembourg. The company has undergone strategic shifts to enhance its product offerings and operational efficiency.

Malik Al Nabhani, the founder, has a background in establishing companies that cater to specialized healthcare needs. SERB has completed a total of 3 deals, with its most recent funding round occurring on June 8, 2023. SERB Pharmaceuticals specializes in providing essential medicines for complex and life-threatening conditions, focusing on rare diseases and emergency care. Their extensive portfolio includes over 70 registered products, prominently featuring emergency medications, medical countermeasures, and a leading collection of antidotes.

These products are designed to address critical medical needs, such as reversing the effects of potent medications in emergency situations or treating complications due to high-dose chemotherapy. SERB's offerings are utilized by healthcare providers across more than 100 countries, including regions in North America, Europe, and Asia, ensuring that clinicians, first responders, and emergency preparedness agencies have access to lifesaving treatments. The company's commitment to urgency in delivering these medicines is supported by trusted partnerships and an integrated supply chain designed to facilitate rapid distribution to healthcare systems and non-profit organizations globally. In the most recent fiscal year of 2022, SERB Pharmaceuticals reported a revenue of USD 82.

69 mn and an EBITDA of USD 31. 89 mn. The company employs a combination of direct sales and partnerships to generate revenue from its diverse portfolio of products, engaging healthcare providers, government agencies, and non-profit organizations as its primary clients. Pricing structures vary based on the product and specific agreements with healthcare providers, with detailed pricing typically negotiated in line with the regulatory requirements of the markets served.

Following the investment from Esas in June 2023, SERB S. a. r. l.

aims to accelerate its growth through a buy-and-build strategy. The company is focusing on expanding its product line with upcoming launches aimed at addressing urgent medical needs in critical care settings. Additionally, SERB is targeting expansion into new markets, particularly in regions across North America and Asia, by the end of 2025. The recent funding will support these initiatives, enabling the company to enhance its operational capacity and broaden its reach into underserved markets.